Klotho Neurosciences (NASDAQ:KLTO) Stock Rating Upgraded by Wall Street Zen

Klotho Neurosciences (NASDAQ:KLTO) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Klotho Neurosciences in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Klotho Neurosciences Stock Up 11.2%

KLTO opened at $0.53 on Friday. The firm has a 50 day moving average price of $0.31 and a 200-day moving average price of $0.46. Klotho Neurosciences has a twelve month low of $0.11 and a twelve month high of $3.91. The stock has a market capitalization of $39.09 million, a price-to-earnings ratio of -1.66 and a beta of 9.02.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KLTO. Jane Street Group LLC purchased a new position in shares of Klotho Neurosciences during the 2nd quarter worth $26,000. XTX Topco Ltd raised its holdings in Klotho Neurosciences by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after purchasing an additional 80,768 shares during the period. Renaissance Technologies LLC purchased a new position in Klotho Neurosciences during the fourth quarter valued at $126,000. Geode Capital Management LLC lifted its position in Klotho Neurosciences by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after purchasing an additional 167,905 shares in the last quarter. Finally, Brummer Multi Strategy AB bought a new stake in Klotho Neurosciences during the fourth quarter valued at about $175,000. 20.07% of the stock is currently owned by institutional investors.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.